Oxford BioMedica PLC (OXBDF)

[marcusl2]

CTL019 JULIET trial interim analysis showed durable complete responses in adults with r/r DLBCL. The three-month overall response rate was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff. Primary analysis at six months confirmed the interim analysis.

CTL019 ELIANA 6-month follow-up data show durable remission rates in children and young adults with r/r B-cell ALL.

CTL119 in combination with ibrutinib showed that eight of nine patients tested had no signs of chronic lymphocytic leukemia in their bone marrow three months after treatment.

Plus BCMA CART in a few months